February 23, 2026 06:06 AM ESTUpdated 11:36 AM
Deals

Up­dat­ed: Gilead to buy cell ther­a­py part­ner Ar­cel­lx in deal val­ued at $7.8B

Lei Lei Wu

News Reporter

Gilead Sci­ences is buy­ing the rest of CAR-T col­lab­o­ra­tor Ar­cel­lx that it doesn’t al­ready own, as its close­ly watched mul­ti­ple myelo­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo Nordisk’s Ca­griSe­ma beat­en by Lil­ly’s Zep­bound in head-to-head obe­si­ty tri­al

Moon­Lake has 'a lot of con­fi­dence' ahead of FDA sub­mis­sion, dis­clos­es mid-stage arthri­tis win

Flag­ship's Gen­er­ate tar­gets $2B+ val­u­a­tion with Nas­daq IPO

Ex­clu­sive: First test of gene ther­a­py for rare form of autism is un­der­way

Mer­ck re­or­ga­nizes; Black­stone to fund tri­als for J&J drug

sponsored

Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

A service from the Financial Times